Dendreon Jumps to Fresh Highs Following Medicare Ruling
March 31, 2011 at 12:40 PM EDT
Shares of Dendreon Corporation (DNDN) are higher again on Thursday, gaining 3.46 percent to $36.77, after rising to $37.03 earlier, the highest PPS intraday since Jan. 18. The stock is attracting significant volume after Dendreon’s Provenge prostate cancer treatment, which costs $93,000 per patient, was approved to be covered by Medicare. The Centers for Medicare [...]
